Clinically, astrocytic damage is reflected by elevated levels of soluble GFAP in CSF, distinguishing NMOSD from MS patients who show elevated levels of markers for myelin damage such as myelin basic protein in the CSF (6). The gene discussed is GFAP; the disease is myeloid sarcoma.